Comparable stake leader
Baselake Partners, LP
SEC ownership of TherapeuticsMD, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000025743.
Disclosed value leader
John C.k. Milligan IV
Comparable rows
46/50
Latest evidence
30 Jun 2026
- Public ticker
- TXMD on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Baselake Partners, LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
46 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Baselake Partners, LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000025743
- Issuer location
- Boca Raton, FL
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of TherapeuticsMD, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Baselake Partners, LP
Disclosed value leader
John C.k. Milligan IV
Comparable rows
46/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 6.8%
4 rows are not safely comparable across share classes.
13D/G row: Baselake Partners, LP
Showing 1-8 of 50 holder rows.
Quick read
Baselake Partners, LP leads the comparable SEC ownership view at 6.8%.
46 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Baselake Partners, LP's linked filing trail.
Comparable ownership
Top 5
Baselake Partners, LP
6.8%
Clearline Capital LP
5.5%
Rubric Capital Management LP
10%
VANGUARD CAPITAL MANAGEMENT LLC
3%
Tejara Capital Ltd
3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Baselake Partners, LP |
13D/G
|
6.8%
|
$1,668,383
790,703 shares
|
+$387,231 | 30 Jun 2026 |
| Clearline Capital LP |
13F
13D/G
Company
|
5.5%
from 13D/G
|
$1,403,841
635,222 shares
|
— | 30 Jun 2026 |
| Rubric Capital Management LP |
3/4/5
13F
Director, Other*, 10%+ Owner · Company
|
10%
from 13F
|
$6,718,950
2,946,908 shares
|
— | 15 Nov 2023 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3%
|
$781,670
353,697 shares
|
— | 30 Jun 2026 |
| Tejara Capital Ltd |
13F
Company
|
3%
|
$761,305
344,482 shares
|
— | 30 Jun 2026 |
| ADAR1 Capital Management, LLC |
13F
Company
|
2.9%
|
$756,808
342,447 shares
|
— | 30 Jun 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
1.3%
|
$323,984
146,599 shares
|
— | 30 Jun 2026 |
| MORGAN STANLEY |
13F
Company
|
1.1%
|
$285,569
129,217 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$14,031.
Buys
$14,031
Insiders: 1
Sells
$0
Insiders: 0
Net
+$14,031
Shares: +8,400
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 8,400
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 8,400 | 0 | $14,031 | $0 | +$14,031 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 20 reporting-owner rows connected to TherapeuticsMD, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
20
Largest Forms 3/4/5 holder
John C.k. Milligan IV
Net 12M change
+$14,031
Latest report
23 Dec 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| John C.k. Milligan IV | Secretary/CEO of subsidiary | $12,698,322 | Mixed | 10 May 2021 | ||
| Hugh O'Dowd | Chief Executive Officer | $11,415,713 | Mixed | 31 Mar 2022 | ||
| Rubric Capital Management LP | Director, Other*, 10%+ Owner | $6,718,950 | Mixed | 15 Nov 2023 | ||
| Robert G. Finizio | CEO, Director | $5,305,888 | Mixed | 01 Jul 2021 | ||
| James Darecca | Chief Financial Officer | $1,857,402 | Mixed | 10 Aug 2021 | ||
| Edward Borkowski | EVP, Operations | $1,326,472 | Mixed | 01 Jul 2021 | ||
| J. Martin Carroll | Director | $239,268 | Mixed | 10 Aug 2021 | ||
| Michael C. Donegan | Prin. Fin. and Acctg. Officer | $138,489 | Mixed | 12 Apr 2023 | ||
| Cooper C. Collins | Director | $104,935 | Mixed | 03 Nov 2025 | ||
| Marlan D. Walker | Chief Executive Officer | $76,534 | Mixed | 03 Nov 2025 | ||
| Tommy G. Thompson | Director | $62,794 | +$14,031 | +29% | Mixed | 23 Dec 2025 |
| Brian Bernick | Co-Chief Executive Officer | $47,065 | Mixed | 06 Dec 2022 | ||
| Angus C. Russell | Director | $18,191 | Mixed | 29 Sep 2022 | ||
| Karen Ling | Director | $18,191 | Mixed | 29 Sep 2022 | ||
| Jules A. Musing | Director | $18,191 | Mixed | 29 Sep 2022 | ||
| Paul Bisaro | Director | $18,191 | Mixed | 29 Sep 2022 | ||
| Joseph Ziegler | Principal Financial Officer | $16,793 | Mixed | 17 Aug 2023 | ||
| Mark A. Glickman | Co-Chief Executive Officer | $15,507 | Mixed | 06 Dec 2022 | ||
| Ph.D. Gail K. Naughton | Director | $14,739 | Mixed | 03 Nov 2025 | ||
| Justin Hunter Roberts | Director | Mixed | 23 Aug 2022 |
Recent insider transactions for TherapeuticsMD, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Tommy G. Thompson | TXMD | Common Stock | Purchase | 56.8% | $14,031 | $1.67 | 8,400 | 23,179 | 23 Dec 2025 | Direct |
| Marlan D. Walker | TXMD | Non-Qualified Stock Option (right to buy) | Award | 67,492 | 67,492 | 03 Nov 2025 | Direct | |||
| Cooper C. Collins | TXMD | Restricted Stock Units | Award | 8,500 | 8,500 | 03 Nov 2025 | Direct | |||
| Tommy G. Thompson | TXMD | Restricted Stock Units | Award | 8,500 | 8,500 | 03 Nov 2025 | Direct | |||
| Ph.D. Gail K. Naughton | TXMD | Restricted Stock Units | Award | 8,500 | 8,500 | 03 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.